Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical and Experimental Pharmacology and Physiology

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1440-1681.12673PMID 27716993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.

  2015cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Denosumab for the treatment of bone metastases in advanced breast cancer.

  2013cited by this paper
• Diagnostic and prognostic use of bone turnover markers.

  2012cited by this paper
• Biochemical-markers for the diagnosis of bone metastasis: a clinical review.

  2012cited by this paper
• Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

  2012cited by this paper
• Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.

  2012cited by this paper
• Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.

  2010cited by this paper
• Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study

  2010cited by this paper
• Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

  2009cited by this paper
• Factors associated with bone metastasis in breast cancer: a preliminary study in an Indonesian population.

  2008cited by this paper
• The evaluation of Tracp5b as a marker for monitoring treatment results of bone metastasis in breast cancer patients

  2008cited by this paper
• Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

  2008cited by this paper
• Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.

  2006cited by this paper
• Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.

  2005cited by this paper
• Bone metabolic markers in bone metastases

  2005cited by this paper
• Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial

  2005cited by this paper
• Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

  2004cited by this paper
• The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation

  2003cited by this paper
• Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.

  2003cited by this paper
• Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

  2003cited by this paper
• Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.

  2002cited by this paper
• Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

  2002cited by this paper
• Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

  2001cited by this paper
• Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.

  1999cited by this paper
• Malignant bone pain: pathophysiology and treatment

  1996cited by this paper
• Alkaline phosphatase isoenzyme patterns in malignant disease.

  1992cited by this paper

• Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature

  2025cites this paper
• Biochemical markers of bone turnover in osteoporosis

  2021cites this paper
• Effects of palliative radiotherapy and bisphosphonate usage on bone turnover marker levels in cancer patients with osteolytic bone metastases

  2021cites this paper
• Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer

  2020influential citation
• Prognostic Significance of ACP5 in Human Gastric Cancer

  2020cites this paper
• Loading-dose ibandronate improves opioid-resistant headache in locoregionally advanced nasopharyngeal carcinoma patients prior to concurrent chemoradiotherapy

  2020cites this paper
• Rosuvastatin promotes osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis by the Wnt/β-catenin signal.

  2019cites this paper
• Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis

  2017cites this paper
• Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial

  2017cites this paper